Paul Glue1, Bruce Russell2, Natalie J Medlicott2. 1. Psychological Medicine, School of Medical Sciences, University of Otago, PO Box 913, Dunedin, New Zealand. paul.glue@otago.ac.nz. 2. School of Pharmacy, University of Otago, Dunedin, New Zealand.
Abstract
PURPOSE: Ketamine has rapid-onset antidepressant effects in patients with treatment-resistant depression. Common side effects include dissociation (a sense of detachment from reality) and increases in systolic and diastolic blood pressure. The objective of this structured review was to examine the effect of ketamine formulation and route of administration on its pharmacokinetics, safety and tolerability, to identify formulation characteristics and routes of administration that might minimise side effects. METHODS: This was a structured review of published ketamine pharmacokinetics, safety and tolerability data for any ketamine formulation. The ratio of ketamine:norketamine was calculated from reported Cmax values, as a measure of first pass metabolism. The effect of formulation and route of administration on safety was evaluated by measuring mean changes in systolic blood pressure and tolerability by changes in dissociation ratings. Data were correlated using Spearman's method. RESULTS: A total of 41 treatment arms were identified from 21 publications, and included formulation development studies in healthy volunteers, and studies in clinical populations (patients undergoing anaesthesia, or being treated for pain or depression). Ketamine:norketamine ratios were strongly positively correlated with change in dissociation ratings (r = 0.89) and change in blood pressure (r = 0.96), and strongly negatively correlated with ketamine Tmax (r = - 0.87; p < 0.00001 for all). Ketamine Tmax strongly positively correlated with a change in dissociation ratings (r = - 0.96) and change in blood pressure (r = - 0.99; p < 0.00001 for all). CONCLUSION: Ketamine formulations that maximize first pass metabolism and delay Tmax will be better tolerated and safer than formulations which lack those characteristics.
PURPOSE:Ketamine has rapid-onset antidepressant effects in patients with treatment-resistant depression. Common side effects include dissociation (a sense of detachment from reality) and increases in systolic and diastolic blood pressure. The objective of this structured review was to examine the effect of ketamine formulation and route of administration on its pharmacokinetics, safety and tolerability, to identify formulation characteristics and routes of administration that might minimise side effects. METHODS: This was a structured review of published ketamine pharmacokinetics, safety and tolerability data for any ketamine formulation. The ratio of ketamine:norketamine was calculated from reported Cmax values, as a measure of first pass metabolism. The effect of formulation and route of administration on safety was evaluated by measuring mean changes in systolic blood pressure and tolerability by changes in dissociation ratings. Data were correlated using Spearman's method. RESULTS: A total of 41 treatment arms were identified from 21 publications, and included formulation development studies in healthy volunteers, and studies in clinical populations (patients undergoing anaesthesia, or being treated for pain or depression). Ketamine:norketamine ratios were strongly positively correlated with change in dissociation ratings (r = 0.89) and change in blood pressure (r = 0.96), and strongly negatively correlated with ketamine Tmax (r = - 0.87; p < 0.00001 for all). Ketamine Tmax strongly positively correlated with a change in dissociation ratings (r = - 0.96) and change in blood pressure (r = - 0.99; p < 0.00001 for all). CONCLUSION:Ketamine formulations that maximize first pass metabolism and delay Tmax will be better tolerated and safer than formulations which lack those characteristics.
Entities:
Keywords:
Dissociation; First pass metabolism; Ketamine formulation; Pharmacokinetics; Safety
Authors: Rajib K Paul; Nagendra S Singh; Mohammed Khadeer; Ruin Moaddel; Mitesh Sanghvi; Carol E Green; Kathleen O'Loughlin; Marc C Torjman; Michel Bernier; Irving W Wainer Journal: Anesthesiology Date: 2014-07 Impact factor: 7.892
Authors: C K Loo; V Gálvez; E O'Keefe; P B Mitchell; D Hadzi-Pavlovic; J Leyden; S Harper; A A Somogyi; R Lai; C S Weickert; P Glue Journal: Acta Psychiatr Scand Date: 2016-03-30 Impact factor: 6.392
Authors: Robert A Schoevers; Tharcila V Chaves; Sonya M Balukova; Marije aan het Rot; Rudie Kortekaas Journal: Br J Psychiatry Date: 2016-02 Impact factor: 9.319
Authors: Ying Xu; Maree Hackett; Gregory Carter; Colleen Loo; Verònica Gálvez; Nick Glozier; Paul Glue; Kyle Lapidus; Alexander McGirr; Andrew A Somogyi; Philip B Mitchell; Anthony Rodgers Journal: Int J Neuropsychopharmacol Date: 2016-04-20 Impact factor: 5.176
Authors: Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould Journal: Nature Date: 2016-05-04 Impact factor: 49.962